<DOC>
	<DOCNO>NCT01903928</DOCNO>
	<brief_summary>This study evaluate safety tolerability therapeutic vaccine , ASP0113 , subject undergoing allogeneic HCT . The occurrence CMV viremia immunogenicity also assess .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability Therapeutic Vaccine , ASP0113 , Subjects Undergoing Allogeneic Hematopoietic Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject plan undergo either follow : Sibling Donor Transplant 7/8 Human Leukocyte Antigen ( HLA ) A , B , C , DRß1 match utilize high resolution type 8/8 ( HLA ) A , B , C , DRß1 match utilize low high resolution type . Unrelated Donor Transplant 7/8 8/8 HLAA , B , C , DRß1 match utilize high resolution type . Subject one follow underlying disease : Acute myeloid leukemia ( AML ) /Acute lymphoblastic leukemia ( ALL ) / Acute undifferentiated leukemia ( AUL ) /Acute biphenotypic leukemia / Chronic myelogenous leukemia ( CML ) / Chronic lymphocytic leukemia ( CLL ) / myelodysplastic syndrome ( ) ( MDS ) Subject schedule receive allogeneic peripheral blood stem cell ( PBSC ) bone marrow transplant ( BMT ) treatment hematologic disorder Subject active CMV disease infection receive treatment active CMV disease infection within 90 day prior transplant Subject plan CMV prophylactic therapy antiviral drug CMVspecific immunoglobulin Subject modify hematopoietic cell transplant comorbidity index ( HCTCI ) score &gt; 3 Subject know positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen hepatitis C ribonucleic acid ( RNA ) Subject receive follow substance treatment : Tcell depletion donor cell product . Alemtuzumab within 60 day prior transplant , include condition regimen . Subjects treatment alemtuzumab plan time 60 day prior one year posttransplant enrol trial . Administration CMV vaccine , include prior exposure ASP0113 . Subject receive allogeneic stem cell transplant within one year prior transplant Subject current malignancy addition malignancy treat study subject history malignancy Subject unstable medical psychiatric condition , include history illicit drug ( ) alcohol abuse Investigator believe interfere protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>cytomegalovirus</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>transplantation</keyword>
	<keyword>HCT</keyword>
</DOC>